Eyelash trichomegaly is an uncommon drug-associated sequelae experienced during 
treatment with epidermal growth factor receptor (EGFR) inhibitors. Elongation of 
the eyelashes induced by these agents has predominantly been observed in 
oncology patients with either colorectal or lung cancer. It is most frequently 
associated with cetuximab and erlotinib; however, it has also been described in 
individuals treated with gefitinib or panitumumab. We describe 
cetuximab-associated eyelash trichomegaly in a woman with metastatic rectal 
carcinoma. We review the clinical presentation, adverse effects, and management 
of EGFR inhibitor-related eyelash trichomegaly. The long eyelashes are not a 
drug-limiting adverse effect and some patients consider the change to be 
cosmetically enhancing. Trimming the lashes with scissors can usually ameliorate 
local symptoms. The eyelashes often return to their original length at variable 
time periods after EGFR inhibitor therapy is discontinued.